| Description |
KDU731, an orally active C. parvum PI4K inhibitor with an IC50 value of 25 nM, blocks Cryptosporidium infection in vitro and in vivo[1][2]. KDU731 is a promising drug candidate for the treatment of diarrhea caused by Cryptosporidium and meets a broad range of safety[2].
|
| Related Catalog |
|
| Target |
PI4K
|
| In Vivo |
KDU731 (orally administration; 7 or 10mg/kg; 16 days) has potent activity against Cryptosporidium in immunocompromised IFN-γ KO mice and dramatically reduces oocyst shedding[2]. KDU731 (orally administration; 5 mg/kg; every 12 hours for 7 days) is tolerated in all calves, and treated calves shed significantly fewer oocysts than vehicle treated calves in their stool[2]. Animal Model: 6-8 week old C57BL/6 IFN-γ-knockout mice with 10,000 oocysts[1] Dosage: 7 or 10 mg/kg Administration: Orally administration; 7 or 10 mg/kg; 16 days Result: Resulted in significant reduction of oocyst shedding. Animal Model: Neonatal calves with 5 x 107 oocysts[1] Dosage: 5 mg/kg Administration: Orally administration; 5 mg/kg; every 12 hours for 7 days Result: Resulted in significant reduction of oocyst shedding in treated calves in their stool.
|
| References |
[1]. Ward HD, et al. New Tools for Cryptosporidium Lead to New Hope for Cryptosporidiosis. Trends Parasitol. 2017 Sep;33(9):662-664. [2]. Manjunatha UH, et al. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis. Nature. 2017 Jun 15;546(7658):376-380.
|
